Tasso and UBC Announce Partnership
At-home blood sample collection and analysis solutions for post-approval research through joint offering.
Tasso, Inc., United BioSource LLC (UBC) have partnered to bring Tasso’s devices for at-home, clinical-grade blood sample collection and end-to-end collection and analysis solutions with UBC’s late-stage research expertise in evidence development and participant support services.
Research utilizing the joint offering will be powered by Tasso’s integrated solutions to streamline blood sample collection and analysis. After sponsors provide a list of samples needed, Tasso will handle shipping at-home blood collection kits directly to research participants, manage transport of samples to an analytical laboratory that has validated the specific test(s) needed, and communicate lab results back to the sponsor. The fully integrated Tasso Connect portal will ensure samples can be tracked with out-of-the-box functionality, and for seamless connectivity, partners can link with their own systems through Tasso’s API integration.
Tasso and UBC have recently been awarded a late-stage biomarker monitoring study.
Reference: Tasso and UBC Partner to Advance Decentralized Sample Collection and Analysis Solutions for Post-Approval Research. Seattle and Blue Bell, PA, June 27, 2023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
